Remove 2010 Remove Disease Remove RNA
article thumbnail

Afimetoran

New Drug Approvals

US10071079, Example 15 Ref WO2018005586 [link] The invention further pertains to pharmaceutical compositions containing at least one compound according to the invention that are useful for the treatment of conditions related to TLR modulation, such as inflammatory and autoimmune diseases, and methods of inhibiting the activity of TLRs in a mammal.

RNA 62
article thumbnail

Roche to launch SARS-CoV-2 Rapid Antigen Test in countries accepting CE mark, allowing fast triage decisions at point of care

The Pharma Data

We are working relentlessly to deliver solutions that help alleviate some of the healthcare burden with reliable SARS-CoV-2 testing solutions as we learn more about the disease and how it affects people around the world.”. SARS-CoV-2 Rapid Antigen Test package insert [2] European Centre for Disease Prevention and Control.

Virus 52
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

TACACICLIB, AUR-102, AURIGENE

New Drug Approvals

The present invention is directed to methods of preparation of compound of formula (I) that is useful for inhibiting Cyclin-dependent kinase 7 (CDK7) and for treating diseases or disorders mediated thereby. As a TFIIH subunit, CDK7 phosphorylates the CTD (Carboxy-Terminal-Domain) of the largest subunit of RNA polymerase II (pol II).

article thumbnail

A Molecular Portrait of ALS and FTD

Drug Target Review

Published on bit.bio’s website, this article authored by Dr Tony Oosterveen dives into the close relationship between FTD and ALS with a focus on mechanisms underlying the neuropathology of both diseases. ALS is the most common motor neuron disease and is estimated to affect more than 80,000 people worldwide.

RNA 98
article thumbnail

Experimental Myotonic Dystrophy Treatment Teams Monoclonal Antibody and siRNA

PLOS: DNA Science

Myotonic dystrophy type 1 (DM1), an inherited disease affecting muscles, was one of the first described “expanding repeat” disorders. Although it improves symptoms by increasing the ability to relax muscles, it does not affect the underlying cause of the disease.

article thumbnail

Cave Coronavirus in Wuhan Lab Seeded COVID – The Truth Has Always Been Out There, in the Genetics

PLOS: DNA Science

The most compelling evidence for the origin lies in the RNA genome sequence similarities between RaTG13 and SARS-CoV-2 – specifically, a part that encodes the “furin binding site” of the spike protein with which the virus adheres to host cells. RaTG13 likely wasn’t the only stop on the evolutionary road to SARS-CoV-2.

Virus 52
article thumbnail

Codon Digest: Seeing Colors After Gene Therapy

Codon

CNGA3-achromatopsia is a hereditary disease that causes people to see in shades of gray. They’re talking about a patient who has a rare genetic disease. Because it turns out that at least half of them , in humans, also bind to RNA molecules. How do transcription factors couple up with the correct RNA molecule?